Skip to content

A pilot study for hematopoietic stem cell transplantation with post-transplantation cyclophosphamide and anti-thymoglobulin from HLA-mismatched related donor for non-malignant diseases (Halo-NM)

A pilot study for hematopoietic stem cell transplantation with post-transplantation cyclophosphamide and anti-thymoglobulin from HLA-mismatched related donor for non-malignant diseases (Halo-NM) - A pilot study for SCT from HLA-mismatched donor for non-malignant diseases

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000026159
Enrollment
9
Registered
2017-03-01
Start date
2017-03-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-malignant diseases (bone marrow failure, immunodeficiency, inborn errors of metabolism)

Interventions

Conditioning regimen with anti-thymocyte globulin. Stem cell transplantation at day 0. Cyclophosphamide at day 3 and 4.

Sponsors

National Center for Child Health and Development
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Diagnosed as bone marrow failure, immunodeficiency, or inborn errors of metabolism 2) Fanconi anemia is excluded for bone marrow failure. 3) No HLA 5/6 (A, B, DR) or more matched related donor 4) No HLA 6/6 (A, B, DR) matched unrelated donor 5) Transplantation from 2- or more-antigen mismatched related donor 6) Age at transplantation <25 years 7) ECOG Performance status: 0-2 8) Sufficient organ function, as follows; a. T-Bil <= 1.5 mg/dl b. Serum creatinine <= 0.8 mg/dl (age <5y), <= 1.2 mg/dl (age 5-9y), <= 1.5 mg/dl (10y or older) c. Ejection fraction 45% or better, and QTfc <0.45 sec 9) Obtained informed consent from a guardian of the patient

Exclusion criteria

Exclusion criteria: 1. Effusion with grade 2 or worse at CTCAE ver 4.0 2. Uncontrolled infection 3. Severe psychological disorders 4. Pregnant or suspected pregnancy 5. Not eligible for this study at the discretion of the investigator.

Design outcomes

Primary

MeasureTime frame
Incidence of events (acute GVHD grade III or more, graft failure, death) by day 30

Countries

Japan

Contacts

Public ContactMotohiro Kato

National Center for Child Health and Development Children's Cancer Center

kato-mt@ncchd.go.jp03-3416-0181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026